Literature DB >> 26956718

CD30 Receptor-Targeted Lentiviral Vectors for Human Induced Pluripotent Stem Cell-Specific Gene Modification.

Thorsten Friedel1, Sabine Jung-Klawitter2, Attila Sebe2, Franziska Schenk3, Ute Modlich3, Zoltán Ivics2, Gerald G Schumann2, Christian J Buchholz1, Irene C Schneider1.   

Abstract

Cultures of induced pluripotent stem cells (iPSCs) often contain cells of varying grades of pluripotency. We present novel lentiviral vectors targeted to the surface receptor CD30 (CD30-LV) to transfer genes into iPSCs that are truly pluripotent as demonstrated by marker gene expression. We demonstrate that CD30 expression is restricted to SSEA4(high) cells of human iPSC cultures and a human embryonic stem cell line. When CD30-LV was added to iPSCs during routine cultivation, efficient and exclusive transduction of cells positive for the pluripotency marker Oct-4 was achieved, while retaining their pluripotency. When added during the reprogramming process, CD30-LV solely transduced cells that became fully reprogrammed iPSCs as confirmed by co-expression of endogenous Nanog and the reporter gene. Thus, CD30-LV may serve as novel tool for the selective gene transfer into PSCs with broad applications in basic and therapeutic research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26956718     DOI: 10.1089/scd.2015.0386

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  2 in total

1.  CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Authors:  Julia D S Hanauer; Benjamin Rengstl; Dina Kleinlützum; Johanna Reul; Anett Pfeiffer; Thorsten Friedel; Irene C Schneider; Sebastian Newrzela; Martin-Leo Hansmann; Christian J Buchholz; Alexander Muik
Journal:  Oncotarget       Date:  2018-01-12

2.  In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome.

Authors:  Anett Pfeiffer; Frederic B Thalheimer; Sylvia Hartmann; Annika M Frank; Ruben R Bender; Simon Danisch; Caroline Costa; Winfried S Wels; Ute Modlich; Renata Stripecke; Els Verhoeyen; Christian J Buchholz
Journal:  EMBO Mol Med       Date:  2018-11       Impact factor: 12.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.